• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?

作者信息

Omarjee Loukman, Meilhac Olivier, Perrot Frédérique, Janin Anne, Mahe Guillaume

机构信息

Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France.

Université de La Réunion, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F-97410, France.

出版信息

Clin Immunol. 2020 Jul;216:108468. doi: 10.1016/j.clim.2020.108468. Epub 2020 May 21.

DOI:10.1016/j.clim.2020.108468
PMID:32445671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7240255/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4034/7240255/c5db4f040257/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4034/7240255/c5db4f040257/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4034/7240255/c5db4f040257/gr1_lrg.jpg

相似文献

1
Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?替格瑞洛能否用于预防新型冠状病毒肺炎（COVID-19）中的脓毒症诱导的凝血病？
Clin Immunol. 2020 Jul;216:108468. doi: 10.1016/j.clim.2020.108468. Epub 2020 May 21.
2
Ticagrelor Can Be an Important Agent in the Treatment of Severe COVID-19 Patients with Myocardial Infarction.替格瑞洛可成为治疗重症新冠肺炎合并心肌梗死患者的重要药物。
Balkan Med J. 2020 Jun 1;37(4):233-233. doi: 10.4274/balkanmedj.galenos.2020.2020.4.100. Epub 2020 Apr 24.
3
Thromboinflammatory response in SARS-CoV-2 sepsis.新型冠状病毒2型脓毒症中的血栓炎症反应。
Med Leg J. 2020 Jul;88(2):78-80. doi: 10.1177/0025817220926915. Epub 2020 Jun 3.
4
[Coagulopathy and COVID-19. Recommendations for a changing reality].[凝血功能障碍与2019冠状病毒病。应对不断变化的现实的建议]
Medicina (B Aires). 2020;80(5):505-511.
5
Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy.新型冠状病毒肺炎肺炎中的免疫血栓调节紊乱与呼吸衰竭和凝血病有关。
Circulation. 2020 Sep 22;142(12):1176-1189. doi: 10.1161/CIRCULATIONAHA.120.048488. Epub 2020 Jul 28.
6
Sars-CoV-2 Induced Coagulopathy and Prognosis in Hospitalized Patients: A Snapshot from Italy.新型冠状病毒肺炎住院患者中严重急性呼吸综合征冠状病毒2诱导的凝血病与预后：来自意大利的一则简讯
Thromb Haemost. 2020 Aug;120(8):1233-1236. doi: 10.1055/s-0040-1712918. Epub 2020 May 26.
7
Comparison of clinical laboratory tests between bacterial sepsis and SARS-CoV-2-associated viral sepsis.细菌脓毒症与 SARS-CoV-2 相关病毒性脓毒症的临床实验室检查比较。
Mil Med Res. 2020 Aug 4;7(1):36. doi: 10.1186/s40779-020-00267-3.
8
Immunotherapies for COVID-19: Restoring the immunity could be the priority.针对新冠肺炎的免疫疗法：恢复免疫力可能是首要任务。
Anaesth Crit Care Pain Med. 2020 Jun;39(3):385. doi: 10.1016/j.accpm.2020.05.009. Epub 2020 May 20.
9
COVID-19 Coagulopathy: Considerations for Urologists.新型冠状病毒肺炎凝血功能障碍：泌尿外科医生的考量
J Urol. 2020 Oct;204(4):640-641. doi: 10.1097/JU.0000000000001144. Epub 2020 May 18.
10
Several neonates reported positive for COVID-19.几名新生儿的新冠病毒检测呈阳性。
Infect Dis (Lond). 2020 Aug;52(8):575-576. doi: 10.1080/23744235.2020.1762920. Epub 2020 May 19.

引用本文的文献

1
The Mechanisms of Sepsis Induced Coagulation Dysfunction and Its Treatment.脓毒症诱导凝血功能障碍的机制及其治疗
J Inflamm Res. 2025 Feb 3;18:1479-1495. doi: 10.2147/JIR.S504184. eCollection 2025.
2
Impact of antiplatelets, anticoagulants and cyclic nucleotide stimulators on neutrophil extracellular traps (NETs) and inflammatory markers during COVID-19.抗血小板药物、抗凝剂和环核苷酸刺激剂对新型冠状病毒肺炎期间中性粒细胞胞外诱捕网（NETs）和炎症标志物的影响
J Thromb Thrombolysis. 2025 Feb;58(2):199-209. doi: 10.1007/s11239-024-03057-z. Epub 2024 Nov 15.
3
A deep learning drug screening framework for integrating local-global characteristics: A novel attempt for limited data.

本文引用的文献

1
Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms.白细胞介素-17A（IL-17A）是先天性和适应性免疫的关键分子，及其在与COVID-19相关的血栓形成和血管机制中的潜在作用。
Autoimmun Rev. 2020 Jul;19(7):102572. doi: 10.1016/j.autrev.2020.102572. Epub 2020 May 3.
2
COVID-19 pathophysiology: A review.新型冠状病毒肺炎的病理生理学：综述。
Clin Immunol. 2020 Jun;215:108427. doi: 10.1016/j.clim.2020.108427. Epub 2020 Apr 20.
3
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.
一种用于整合局部-全局特征的深度学习药物筛选框架：针对有限数据的新尝试。
Heliyon. 2024 Jul 14;10(14):e34244. doi: 10.1016/j.heliyon.2024.e34244. eCollection 2024 Jul 30.
4
A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.嘌呤能信号通路在治疗 COVID-19 中的作用的系统评价。
Int J Mol Sci. 2023 Apr 26;24(9):7865. doi: 10.3390/ijms24097865.
5
Purinergic signaling pathway in severe COVID-19.嘌呤能信号通路在重症 COVID-19 中的作用。
Curr Opin Pharmacol. 2023 Jun;70:102379. doi: 10.1016/j.coph.2023.102379. Epub 2023 Mar 23.
6
A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection.一项评估 Aggrenox 在 SARS-CoV-2 感染患者中的疗效的随机对照试验。
PLoS One. 2023 Jan 30;18(1):e0274243. doi: 10.1371/journal.pone.0274243. eCollection 2023.
7
Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS.新型冠状病毒肺炎相关急性呼吸窘迫综合征中溶栓药物的药物治疗考量
J Intensive Care. 2022 Jul 30;10(1):38. doi: 10.1186/s40560-022-00625-4.
8
The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.嘌呤能信号在抗包括 SARS-CoV-2 在内的病毒方面的潜力。
Front Immunol. 2022 Jun 17;13:904419. doi: 10.3389/fimmu.2022.904419. eCollection 2022.
9
Platelet Megakaryocyte: Who Is the Real Bandleader of Thromboinflammation in Sepsis?血小板 巨核细胞：在脓毒症中，谁才是血栓炎症真正的领衔主演？
Cells. 2022 Apr 30;11(9):1507. doi: 10.3390/cells11091507.
10
In-stent Thrombosis and COVID-19 Infection: Current Insights on the Mechanistic Relationship.支架内血栓形成与 COVID-19 感染：对其发病机制关联的最新认识。
Curr Cardiol Rev. 2023;19(1):e120522204669. doi: 10.2174/1573403X18666220512142019.
抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
4
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
5
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.替格瑞洛联合阿司匹林在急性冠状动脉综合征中的获益与风险：随机 GLOBAL LEADERS 试验的事后分析。
JAMA Cardiol. 2019 Nov 1;4(11):1092-1101. doi: 10.1001/jamacardio.2019.3355.
6
Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers.替格瑞洛联合或不联合阿司匹林对血小板反应性和凝血激活的影响差异：一项在健康志愿者中的随机试验。
Clin Pharmacol Ther. 2020 Feb;107(2):415-422. doi: 10.1002/cpt.1616. Epub 2019 Sep 28.
7
Platelet-Neutrophil Interplay: Insights Into Neutrophil Extracellular Trap (NET)-Driven Coagulation in Infection.血小板-中性粒细胞相互作用：对感染中中性粒细胞胞外诱捕网（NET）驱动凝血的见解
Front Cardiovasc Med. 2019 Jun 20;6:85. doi: 10.3389/fcvm.2019.00085. eCollection 2019.
8
Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia.替格瑞洛降低肺炎患者的血栓炎症标志物水平。
JACC Basic Transl Sci. 2018 Aug 28;3(4):435-449. doi: 10.1016/j.jacbts.2018.05.005. eCollection 2018 Aug.
9
Heparin-Induced Thrombocytopenia.
J Infus Nurs. 2017 Mar/Apr;40(2):98-100. doi: 10.1097/NAN.0000000000000215.
10
Pneumonitis and pulmonary haemorrhage after acute myocardial infarction.急性心肌梗死后的肺炎和肺出血
Clin Med (Lond). 2015 Dec;15(6):591-3. doi: 10.7861/clinmedicine.15-6-591.